A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection

Trial Profile

A Phase 1b, Open-label, Multicenter, Single Dose Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of AK0529 in Infants Hospitalized With Respiratory Syncytial Virus Infection

Discontinued
Phase of Trial: Phase I

Latest Information Update: 04 Jul 2016

At a glance

  • Drugs AK 0529 (Primary)
  • Indications Respiratory syncytial virus infections
  • Focus Adverse reactions
  • Sponsors Ark Biosciences
  • Most Recent Events

    • 28 Jun 2016 Status changed from recruiting to discontinued as we switched this study design to another study per IEC's recommendations.
    • 19 Oct 2015 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
    • 19 Oct 2015 Planned End Date changed from 1 Feb 2016 to 1 Dec 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top